Projected long‐term outcomes in patients with type 1 diabetes treated with fast‐acting insulin aspart vs conventional insulin aspart in the UK setting

Aim To assess the impact of faster aspart vs insulin aspart on long‐term clinical outcomes and costs for patients with type 1 diabetes mellitus ( T1DM ) in the UK setting. Methods The QuintilesIMS CORE D iabetes Model was used to project clinical outcomes and costs over patient lifetimes in a cohort with data on baseline characteristics from the “onset 1” trial. Treatment effects were taken from the 26‐week main phase of the onset 1 trial, with costs and utilities based on literature review. Future costs and clinical benefits were discounted at 3.5% annually. Results Projections indicated that faster aspart was associated with improved discounted quality‐adjusted life expectancy (by 0.13 quality‐adjusted life‐years) vs insulin aspart. Improved clinical outcomes resulted from fewer diabetes‐related complications and a delayed time to their onset with faster aspart. Faster aspart was found to be associated with reduced costs vs insulin aspart (cost savings of £1715), resulting from diabetes‐related complications avoided and reduced treatment costs. Conclusions Faster aspart was associated with improved clinical outcomes and cost savings vs insulin aspart for patients with T1DM in the UK setting.